2024 Topic: Combination therapies against cancer: new opportunities for translational research
The ATM Community is encouraged to consider this joint call from TRANSCAN specific to translational research. Specifically, the main purpose of this call will be design of patient preclinical models for combination therapies. Through chosen projects, this call expects to improve the efficacy of personalized treatment of cancer patients through the development of new combinatorial treatment strategies, based on a better understanding of drug mechanistic functions and of their impact on the disease course. This opportunity is of interest for early-career researchers, as it is mandatory to have at least 1 early-career researcher as principle investigator. As described by TRANSCAN, this opportunity promotes highly innovative and ambitious collaborative projects in translational cancer research at European and international level for projects lasting no more than 3 years. This is the 4th Transnational Call for Research Proposals, with 20+ national/regional funding organizations participating.
Proposals have to cover 1 of 3 specific aims
- Development of new tumour derived models to test new drug combination therapies
- Design and development of high-throughput drug combination screening platforms to test new combination therapies
- Use of immunotherapy and radiotherapy combinations strategies to overcome drug resistance
Evaluation Criteria (each scored using a 0-5 point scoring system)
- Excellence
- Impact
- Quality and efficacy of the implementation
Key Dates
- 5 July 2024 | 3am PT Pre-Proposal Submission Deadline
- 29 November 2024 | 3am PT Full-Proposal Submission Deadline
- 18 October 2024 Invitations for Full-Proposal Submission
- 18 November 2024 Full-proposal submissions open
- May 2025 Funding Decision
- September 2025 Expected Project Start